2.05
price down icon7.66%   -0.17
after-market 시간 외 거래: 2.07 0.02 +0.98%
loading
전일 마감가:
$2.22
열려 있는:
$2.22
하루 거래량:
7.80M
Relative Volume:
1.46
시가총액:
$526.46M
수익:
$403.14M
순이익/손실:
$-22.68M
주가수익비율:
-9.7852
EPS:
-0.2095
순현금흐름:
$-13.09M
1주 성능:
-11.26%
1개월 성능:
-15.98%
6개월 성능:
-24.07%
1년 성능:
+105.18%
1일 변동 폭
Value
$2.03
$2.27
1주일 범위
Value
$2.03
$2.46
52주 변동 폭
Value
$0.6925
$4.175

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
명칭
Esperion Therapeutics Inc
Name
전화
734-887-3903
Name
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
직원
294
Name
트위터
@esperioninc
Name
다음 수익 날짜
2026-03-10
Name
최신 SEC 제출 서류
Name
ESPR's Discussions on Twitter

Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ESPR icon
ESPR
Esperion Therapeutics Inc
2.05 557.28M 403.14M -22.68M -13.09M -0.2095
TAK icon
TAK
Takeda Pharmaceutical Co Adr
17.85 57.12B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
121.11 49.56B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.70 43.86B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
31.77 35.89B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
578.54 25.06B 3.18B 1.33B 1.04B 27.90

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-11-25 개시 Piper Sandler Overweight
2024-12-18 개시 Goldman Neutral
2024-12-17 개시 Cantor Fitzgerald Overweight
2024-06-20 다운그레이드 BofA Securities Neutral → Underperform
2024-01-03 다운그레이드 BofA Securities Buy → Neutral
2023-11-20 재개 JP Morgan Neutral
2023-08-01 업그레이드 Northland Capital Under Perform → Market Perform
2023-06-15 업그레이드 BofA Securities Underperform → Buy
2023-03-16 다운그레이드 BofA Securities Neutral → Underperform
2023-03-16 다운그레이드 Northland Capital Market Perform → Under Perform
2023-03-07 업그레이드 Credit Suisse Underperform → Neutral
2023-02-27 재개 BofA Securities Neutral
2023-02-24 업그레이드 Jefferies Hold → Buy
2023-02-03 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-08-03 다운그레이드 Credit Suisse Neutral → Underperform
2022-05-05 업그레이드 JP Morgan Underweight → Neutral
2022-03-10 개시 H.C. Wainwright Buy
2021-10-19 다운그레이드 Credit Suisse Outperform → Neutral
2021-10-14 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-05-05 다운그레이드 Stifel Buy → Hold
2021-04-26 재개 Credit Suisse Outperform
2021-03-11 개시 Morgan Stanley Equal-Weight
2021-02-12 다운그레이드 Jefferies Buy → Hold
2021-02-09 다운그레이드 Goldman Neutral → Sell
2021-01-15 다운그레이드 BofA Securities Buy → Neutral
2020-11-10 업그레이드 Credit Suisse Neutral → Outperform
2020-09-29 재개 JP Morgan Underweight
2020-08-11 다운그레이드 Credit Suisse Outperform → Neutral
2020-04-01 재개 BofA/Merrill Buy
2020-03-17 업그레이드 Citigroup Neutral → Buy
2020-02-24 다운그레이드 Northland Capital Outperform → Market Perform
2020-02-14 다운그레이드 Citigroup Buy → Neutral
2019-09-16 업그레이드 Goldman Sell → Neutral
2019-05-29 다운그레이드 Goldman Neutral → Sell
2019-05-06 업그레이드 BofA/Merrill Underperform → Neutral
2019-04-26 업그레이드 Goldman Sell → Neutral
2019-03-13 업그레이드 JP Morgan Underweight → Neutral
2019-01-07 재확인 Needham Strong Buy
2018-12-13 개시 Goldman Sell
2018-10-29 업그레이드 Northland Capital Market Perform → Outperform
2018-10-16 개시 BTIG Research Buy
2018-08-17 업그레이드 Citigroup Neutral → Buy
2018-07-11 다운그레이드 Northland Capital Outperform → Market Perform
2018-05-03 다운그레이드 JP Morgan Neutral → Underweight
2018-05-02 다운그레이드 BofA/Merrill Buy → Underperform
모두보기

Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스

pulisher
Apr 14, 2026

Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Apr 14, 2026
pulisher
Apr 13, 2026

Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance

Apr 13, 2026
pulisher
Apr 13, 2026

Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference - Yahoo Finance

Apr 13, 2026
pulisher
Apr 13, 2026

Personalized treatments advance as Esperion Therapeutics urges broader use of hsCRP in heart care - Traders Union

Apr 13, 2026
pulisher
Apr 09, 2026

Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore

Apr 09, 2026
pulisher
Apr 09, 2026

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Apr 09, 2026
pulisher
Apr 09, 2026

Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN

Apr 09, 2026
pulisher
Apr 09, 2026

Guidance Update: What is the next catalyst for Esperion Therapeutics Inc2026 Drop Watch & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Apr 09, 2026
pulisher
Apr 08, 2026

Movement Recap: What are Esperion Therapeutics Incs technical support levels2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn

Apr 08, 2026
pulisher
Apr 08, 2026

ESPR Forecast, Price Target & Analyst Ratings | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill

Apr 08, 2026
pulisher
Apr 07, 2026

Esperion Therapeutics Stock Dips After Q4 Earnings Miss Expectations - StocksToTrade

Apr 07, 2026
pulisher
Apr 07, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 07, 2026
pulisher
Apr 06, 2026

Ann Arbor pharmaceutical company acquires nasal spray treatment manufacturer - MLive.com

Apr 06, 2026
pulisher
Apr 06, 2026

Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co. - MarketBeat

Apr 06, 2026
pulisher
Apr 05, 2026

This Cheap $2.60's Stock Is A Great Investment With Huge Guideline News. Top 3 Analysts Say Strong Buy $9 to $16 - Moomoo

Apr 05, 2026
pulisher
Apr 04, 2026

ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK

Apr 03, 2026
pulisher
Apr 03, 2026

Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail

Apr 03, 2026
pulisher
Apr 03, 2026

Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada

Apr 03, 2026
pulisher
Apr 03, 2026

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Sahm

Apr 03, 2026
pulisher
Apr 03, 2026

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times

Apr 03, 2026
pulisher
Apr 02, 2026

Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026SEC Filing - TradingView — Track All Markets

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - marketscreener.com

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView — Track All Markets

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion sells Japan royalty rights for $50 million to Athyrium - Investing.com

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion completes acquisition of Corstasis Therapeutics - Investing.com

Apr 02, 2026
pulisher
Apr 02, 2026

Athyrium Capital Management and Esperion Enter Into $50 - GlobeNewswire

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union

Apr 02, 2026
pulisher
Apr 02, 2026

Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) - Bitget

Apr 02, 2026
pulisher
Apr 01, 2026

Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com

Apr 01, 2026
pulisher
Apr 01, 2026

Esperion Therapeutics, Inc. completed the acquisition of Corstasis Therapeutics Inc. - marketscreener.com

Apr 01, 2026
pulisher
Apr 01, 2026

New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo

Apr 01, 2026
pulisher
Apr 01, 2026

Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat

Apr 01, 2026
pulisher
Apr 01, 2026

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz

Apr 01, 2026
pulisher
Mar 31, 2026

Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN

Mar 31, 2026
pulisher
Mar 31, 2026

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget

Mar 31, 2026
pulisher
Mar 31, 2026

Esperion to acquire Corstasis for $75M upfront payment - MSN

Mar 31, 2026
pulisher
Mar 31, 2026

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat

Mar 31, 2026
pulisher
Mar 31, 2026

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Mar 31, 2026
pulisher
Mar 31, 2026

Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan

Mar 31, 2026
pulisher
Mar 30, 2026

US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union

Mar 30, 2026
pulisher
Mar 30, 2026

Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada

Mar 30, 2026
pulisher
Mar 30, 2026

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget

Mar 30, 2026
pulisher
Mar 30, 2026

Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union

Mar 30, 2026
pulisher
Mar 30, 2026

Esperion Showcases New Data from CLEAR Outcomes - GlobeNewswire

Mar 30, 2026

Esperion Therapeutics Inc (ESPR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
RDY RDY
$13.13
price down icon 1.06%
$24.11
price up icon 1.05%
$130.81
price up icon 3.55%
RGC RGC
$30.11
price down icon 6.61%
$13.91
price up icon 0.58%
$578.54
price up icon 0.16%
자본화:     |  볼륨(24시간):